You are here

GW Pharma

Quiet times return for biopharma takeouts

Quiet times return for biopharma takeouts

EP Vantage

Five Prime Therapeutics

Gilead Sciences

Horizon Therapeutics

Jazz Pharmaceutical

Flag link:

Jazz CEO Bruce Cozadd campaigned for 6 months to buy GW Pharma. A 90% premium sealed the deal — along with $17.6M in ‘retention’ incentives

Jazz CEO Bruce Cozadd campaigned for 6 months to buy GW Pharma. A 90% premium sealed the deal — along with $17.6M in ‘retention’ incentives

Endpoints

Jazz Pharmaceuticals

Flag link:

Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4

Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4

Pharmaforum

pharma industry

Jazz Pharmaceuticals

Flag link:

GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4

GW Pharmaceuticals Beats on Revenue, Bottom Line for Q4

Motley Fool

Flag link:

Jazz Pharma to acquire GW Pharma for $7.2 billion, adding CBD-based treatment for severe epilepsy

Jazz Pharma to acquire GW Pharma for $7.2 billion, adding CBD-based treatment for severe epilepsy

Stat

Flag link:

GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.

GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.

BioSpace

multiple sclerosis

Flag link:

Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?

Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?

Endpoints

Ovid Therapeutics

clinical trials

Dravet syndrome

Lennox-Gastaut Syndrome

Flag link:

GW Pharmaceuticals' Epidiolex Wins New FDA Approvals

GW Pharmaceuticals' Epidiolex Wins New FDA Approvals

Motley Fool

tuberous sclerosis complex

Flag link:

3 Biotech Stocks With Big Incoming Catalysts

3 Biotech Stocks With Big Incoming Catalysts

Motley Fool

valoctocogene roxaparvovec

Flag link:

How GW Pharmaceuticals Hit a Home Run in Q1

How GW Pharmaceuticals Hit a Home Run in Q1

Motley Fool

Flag link:

GW Pharma tops list of UK R&D spenders

GW Pharma tops list of UK R&D spenders

Pharmaforum

Flag link:

Zogenix's Positive Clinical Trial Wasn't Positive Enough

Zogenix's Positive Clinical Trial Wasn't Positive Enough

Motley Fool

Lennox-Gastaut Syndrome

clinical trials

Flag link:

Zogenix hands GW a win

Zogenix hands GW a win

EP Vantage

Lennox-Gastaut Syndrome

clinical trials

Flag link:

GW Pharmaceuticals' Preliminary Q4 Revenue of $108 Million Beats Expectations

GW Pharmaceuticals' Preliminary Q4 Revenue of $108 Million Beats Expectations

Motley Fool

Flag link:

Where Will GW Pharmaceuticals Be in 5 Years?

Where Will GW Pharmaceuticals Be in 5 Years?

Motley Fool

Flag link:

The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Yahoo/Benzinga

Bristol-Myers Squibb

Acadia Pharmaceuticals

Cassava Sciences

Magenta Therapeutics

Fortress Biotech

Flag link:

GW's Epidiolex topped sales predictions, but investors bailed. What gives?

GW's Epidiolex topped sales predictions, but investors bailed. What gives?

Fierce Pharma

Flag link:

GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union

GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union

Endpoints

Flag link:

For GW Pharma CEO Justin Gover, The CBD Trend Started 20 Years Ago

For GW Pharma CEO Justin Gover, The CBD Trend Started 20 Years Ago

Xconomy

Flag link:

GW confident epilepsy drug will get NHS funding despite NICE rejection

GW confident epilepsy drug will get NHS funding despite NICE rejection

Pharmaforum

Flag link:

Pages